{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T20:42:15Z","timestamp":1793911335635,"version":"4.8.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T00:00:00Z","timestamp":1767139200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T00:00:00Z","timestamp":1769990400000},"content-version":"vor","delay-in-days":33,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82030052"],"award-info":[{"award-number":["82030052"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["22277031"],"award-info":[{"award-number":["22277031"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Innovative Drug Research and Development-National Science and Technology Major Project","award":["2025ZD1803403"],"award-info":[{"award-number":["2025ZD1803403"]}]},{"name":"Hubei Science and Technology Innovation Talent Program","award":["2023DJC162"],"award-info":[{"award-number":["2023DJC162"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med"],"DOI":"10.1186\/s12916-025-04589-8","type":"journal-article","created":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T00:23:43Z","timestamp":1767140623000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Trop2 immuno-PET\/CT imaging of prostate cancer: a proof-of-concept translational study"],"prefix":"10.1186","volume":"24","author":[{"given":"Xingru","family":"Long","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuxian","family":"An","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuanbingning","family":"Nian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongsheng","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weijun","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoli","family":"Lan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dawei","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,31]]},"reference":[{"issue":"1","key":"4589_CR1","first-page":"93","volume":"389","author":"K Inamura","year":"2023","unstructured":"Inamura K. Screening for prostate cancer. N Engl J Med. 2023;389(1):93.","journal-title":"N Engl J Med"},{"issue":"10","key":"4589_CR2","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1038\/s41585-018-0060-7","volume":"15","author":"NJ Sathianathen","year":"2018","unstructured":"Sathianathen NJ, Konety BR, Crook J, Saad F, Lawrentschuk N. Landmarks in prostate cancer. Nat Rev Urol. 2018;15(10):627\u201342.","journal-title":"Nat Rev Urol"},{"key":"4589_CR3","doi-asserted-by":"crossref","unstructured":"Thoma C, Marshall L. Prostate cancer. Nat Rev Dis Primers. 2021;7(1):8.","DOI":"10.1038\/s41572-021-00249-2"},{"key":"4589_CR4","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.canlet.2022.01.015","volume":"530","author":"J Kang","year":"2022","unstructured":"Kang J, La Manna F, Bonollo F, Sampson N, Alberts IL, Mingels C, et al. Tumor microenvironment mechanisms and bone metastatic disease progression of prostate cancer. Cancer Lett. 2022;530:156\u201369.","journal-title":"Cancer Lett"},{"issue":"2","key":"4589_CR5","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1038\/s41391-023-00667-1","volume":"27","author":"Y Liadi","year":"2024","unstructured":"Liadi Y, Campbell T, Dike P, Harlemon M, Elliott B, Odero-Marah V. Prostate cancer metastasis and health disparities: a systematic review. Prostate Cancer Prostatic Dis. 2024;27(2):183\u201391.","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"11","key":"4589_CR6","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1016\/j.neo.2020.09.002","volume":"22","author":"JE Vellky","year":"2020","unstructured":"Vellky JE, Ricke WA. Development and prevalence of castration-resistant prostate cancer subtypes. Neoplasia. 2020;22(11):566\u201375.","journal-title":"Neoplasia"},{"issue":"4","key":"4589_CR7","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22041551","volume":"22","author":"M Rosellini","year":"2021","unstructured":"Rosellini M, Santoni M, Mollica V, Rizzo A, Cimadamore A, Scarpelli M, et al. Treating prostate cancer by antibody-drug conjugates. Int J Mol Sci. 2021;22(4):1551.","journal-title":"Int J Mol Sci"},{"issue":"3","key":"4589_CR8","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1038\/nrd.2017.227","volume":"17","author":"PJ Carter","year":"2018","unstructured":"Carter PJ, Lazar GA. Next generation antibody drugs: pursuit of the \u201chigh-hanging fruit.\u201d Nat Rev Drug Discov. 2018;17(3):197\u2013223.","journal-title":"Nat Rev Drug Discov"},{"key":"4589_CR9","doi-asserted-by":"publisher","first-page":"1332489","DOI":"10.3389\/fimmu.2023.1332489","volume":"14","author":"X Liu","year":"2023","unstructured":"Liu X, Li J, Deng J, Zhao J, Zhao G, Zhang T, et al. Targeting Trop2 in solid tumors: a look into structures and novel epitopes. Front Immunol. 2023;14:1332489.","journal-title":"Front Immunol"},{"issue":"1","key":"4589_CR10","doi-asserted-by":"publisher","first-page":"e75","DOI":"10.1016\/j.clgc.2015.10.002","volume":"14","author":"B Faltas","year":"2016","unstructured":"Faltas B, Goldenberg DM, Ocean AJ, Govindan SV, Wilhelm F, Sharkey RM, et al. Sacituzumab govitecan, a novel antibody\u2013drug conjugate, in patients with metastatic platinum-resistant urothelial carcinoma. Clin Genitourin Cancer. 2016;14(1):e75-79.","journal-title":"Clin Genitourin Cancer"},{"issue":"16","key":"4589_CR11","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1056\/NEJMoa2028485","volume":"384","author":"A Bardia","year":"2021","unstructured":"Bardia A, Hurvitz SA, Tolaney SM, Loirat D, Punie K, Oliveira M, et al. Sacituzumab govitecan in metastatic triple-negative breast cancer. N Engl J Med. 2021;384(16):1529\u201341.","journal-title":"N Engl J Med"},{"key":"4589_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2023.102572","volume":"118","author":"C Parisi","year":"2023","unstructured":"Parisi C, Mahjoubi L, Gazzah A, Barlesi F. TROP-2 directed antibody-drug conjugates (ADCs): the revolution of smart drug delivery in advanced non-small cell lung cancer (NSCLC). Cancer Treat Rev. 2023;118:102572.","journal-title":"Cancer Treat Rev"},{"issue":"4","key":"4589_CR13","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.1073\/pnas.1905384117","volume":"117","author":"EC Hsu","year":"2020","unstructured":"Hsu EC, Rice MA, Bermudez A, Marques FJG, Aslan M, Liu S, et al. Trop2 is a driver of metastatic prostate cancer with neuroendocrine phenotype via PARP1. Proc Natl Acad Sci U S A. 2020;117(4):2032\u201342.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"4589_CR14","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1016\/j.annonc.2021.03.005","volume":"32","author":"A Bardia","year":"2021","unstructured":"Bardia A, Messersmith WA, Kio EA, Berlin JD, Vahdat L, Masters GA, et al. Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I\/II IMMU-132-01 basket trial. Ann Oncol. 2021;32(6):746\u201356.","journal-title":"Ann Oncol"},{"issue":"12","key":"4589_CR15","doi-asserted-by":"publisher","first-page":"2324","DOI":"10.1158\/1078-0432.CCR-22-1305","volume":"29","author":"JM Sperger","year":"2023","unstructured":"Sperger JM, Helzer KT, Stahlfeld CN, Jiang D, Singh A, Kaufmann KR, et al. Expression and therapeutic targeting of TROP-2 in treatment-resistant prostate cancer. Clin Cancer Res. 2023;29(12):2324\u201335.","journal-title":"Clin Cancer Res"},{"issue":"Suppl 2","key":"4589_CR16","doi-asserted-by":"publisher","first-page":"83S","DOI":"10.2967\/jnumed.116.186940","volume":"58","author":"KL Moek","year":"2017","unstructured":"Moek KL, Giesen D, Kok IC, de Groot DJA, Jalving M, Fehrmann RSN, et al. Theranostics using antibodies and antibody-related therapeutics. J Nucl Med. 2017;58(Suppl 2):83S-90S.","journal-title":"J Nucl Med"},{"issue":"7467","key":"4589_CR17","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1038\/nature12625","volume":"501","author":"RA Burrell","year":"2013","unstructured":"Burrell RA, McGranahan N, Bartek J, Swanton C. The causes and consequences of genetic heterogeneity in cancer evolution. Nature. 2013;501(7467):338\u201345.","journal-title":"Nature"},{"issue":"8","key":"4589_CR18","doi-asserted-by":"publisher","first-page":"3787","DOI":"10.1021\/acs.chemrev.9b00738","volume":"120","author":"W Wei","year":"2020","unstructured":"Wei W, Rosenkrans ZT, Liu J, Huang G, Luo QY, Cai W. Immunopet: concept, design, and applications. Chem Rev. 2020;120(8):3787\u2013851.","journal-title":"Chem Rev"},{"issue":"12","key":"4589_CR19","first-page":"1904","volume":"65","author":"W Huang","year":"2024","unstructured":"Huang W, Cao M, Wu Y, Zhang Y, An S, Pan X, et al. Immuno-PET\/CT imaging of Trop2 with [18F]AlF-RESCA-T4 differentiates lung cancer from inflammation. J Nucl Med. 2024;65(12):1904\u201310.","journal-title":"J Nucl Med"},{"issue":"5","key":"4589_CR20","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1038\/s44321-024-00059-5","volume":"16","author":"W Huang","year":"2024","unstructured":"Huang W, Zhang Y, Cao M, Wu Y, Jiao F, Chu Z, et al. Immunopet imaging of Trop2 in patients with solid tumours. EMBO Mol Med. 2024;16(5):1143\u201361.","journal-title":"EMBO Mol Med"},{"issue":"2","key":"4589_CR21","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1007\/s00259-023-06454-3","volume":"51","author":"W Huang","year":"2024","unstructured":"Huang W, Liang C, Zhang Y, Zhang D, An S, Wu Q, et al. Immunopet imaging of Trop2 expression in solid tumors with nanobody tracers. Eur J Nucl Med Mol Imaging. 2024;51(2):380\u201394.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"4589_CR22","doi-asserted-by":"crossref","unstructured":"Li T, Fu J, Zeng Z, Cohen D, Li J, Chen Q, et al. TIMER2.0 for analysis of tumor-infiltrating immune cells. Nucleic Acids Res. 2020;48(W1):W509\u201314.","DOI":"10.1093\/nar\/gkaa407"},{"issue":"W1","key":"4589_CR23","doi-asserted-by":"publisher","first-page":"W98","DOI":"10.1093\/nar\/gkx247","volume":"45","author":"Z Tang","year":"2017","unstructured":"Tang Z, Li C, Kang B, Gao G, Li C, Zhang Z. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 2017;45(W1):W98-102.","journal-title":"Nucleic Acids Res"},{"issue":"1","key":"4589_CR24","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1038\/s41467-021-27322-4","volume":"13","author":"H Song","year":"2022","unstructured":"Song H, Weinstein HNW, Allegakoen P, Wadsworth MH, Xie J, Yang H, et al. Single-cell analysis of human primary prostate cancer reveals the heterogeneity of tumor-associated epithelial cell states. Nat Commun. 2022;13(1):141.","journal-title":"Nat Commun"},{"key":"4589_CR25","doi-asserted-by":"crossref","unstructured":"Barrett T, Wilhite SE, Ledoux P, Evangelista C, Kim IF, Tomashevsky M, et al. NCBI GEO: archive for functional genomics data sets--update. Nucleic Acids Res. 2013;41(Database issue):D991\u2013995.","DOI":"10.1093\/nar\/gks1193"},{"issue":"3","key":"4589_CR26","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1515\/hsz-2018-0330","volume":"400","author":"G Bala","year":"2019","unstructured":"Bala G, Crauwels M, Blykers A, Remory I, Marschall ALJ, D\u00fcbel S, et al. Radiometal-labeled anti-VCAM-1 nanobodies as molecular tracers for atherosclerosis - impact of radiochemistry on pharmacokinetics. Biol Chem. 2019;400(3):323\u201332.","journal-title":"Biol Chem"},{"issue":"1","key":"4589_CR27","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1038\/s41585-024-00900-z","volume":"22","author":"MK Bakht","year":"2025","unstructured":"Bakht MK, Beltran H. Biological determinants of PSMA expression, regulation and heterogeneity in prostate cancer. Nat Rev Urol. 2025;22(1):26\u201345.","journal-title":"Nat Rev Urol"},{"issue":"5","key":"4589_CR28","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1038\/s43018-023-00539-6","volume":"4","author":"MK Bakht","year":"2023","unstructured":"Bakht MK, Yamada Y, Ku SY, Venkadakrishnan VB, Korsen JA, Kalidindi TM, et al. Landscape of prostate-specific membrane antigen heterogeneity and regulation in AR-positive and AR-negative metastatic prostate cancer. Nat Cancer. 2023;4(5):699\u2013715.","journal-title":"Nat Cancer"},{"issue":"5","key":"4589_CR29","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1016\/j.euf.2021.06.006","volume":"8","author":"B Sheehan","year":"2022","unstructured":"Sheehan B, Guo C, Neeb A, Paschalis A, Sandhu S, de Bono JS. Prostate-specific membrane antigen biology in lethal prostate cancer and its therapeutic implications. Eur Urol Focus. 2022;8(5):1157\u201368.","journal-title":"Eur Urol Focus"},{"issue":"7","key":"4589_CR30","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.162907","volume":"8","author":"E Sayar","year":"2023","unstructured":"Sayar E, Patel RA, Coleman IM, Roudier MP, Zhang A, Mustafi P, et al. Reversible epigenetic alterations mediate PSMA expression heterogeneity in advanced metastatic prostate cancer. JCI Insight. 2023;8(7):e162907.","journal-title":"JCI Insight"},{"issue":"6","key":"4589_CR31","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.3892\/ijo.2012.1649","volume":"41","author":"T Liu","year":"2012","unstructured":"Liu T, Wu LY, Fulton MD, Johnson JM, Berkman CE. Prolonged androgen deprivation leads to downregulation of androgen receptor and prostate-specific membrane antigen in prostate cancer cells. Int J Oncol. 2012;41(6):2087\u201392.","journal-title":"Int J Oncol"},{"issue":"12","key":"4589_CR32","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.7320","volume":"13","author":"R Weiten","year":"2024","unstructured":"Weiten R, Niemann M, Below E, Friker LL, Ralser DJ, Toma M, et al. Preclinical evidence for the use of anti-Trop-2 antibody-drug conjugate Sacituzumab govitecan in cerebral metastasized castration-resistant prostate cancer. Cancer Med. 2024;13(12):e7320.","journal-title":"Cancer Med"},{"issue":"4","key":"4589_CR33","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1016\/j.annonc.2020.02.002","volume":"31","author":"R Ge","year":"2020","unstructured":"Ge R, Wang Z, Montironi R, Jiang Z, Cheng M, Santoni M, et al. Epigenetic modulations and lineage plasticity in advanced prostate cancer. Ann Oncol. 2020;31(4):470\u20139.","journal-title":"Ann Oncol"},{"issue":"6","key":"4589_CR34","doi-asserted-by":"publisher","first-page":"e254","DOI":"10.1016\/S1470-2045(16)30030-4","volume":"17","author":"A Thomas","year":"2016","unstructured":"Thomas A, Teicher BA, Hassan R. Antibody-drug conjugates for cancer therapy. Lancet Oncol. 2016;17(6):e254-62.","journal-title":"Lancet Oncol"},{"issue":"6","key":"4589_CR35","doi-asserted-by":"publisher","first-page":"2225","DOI":"10.1007\/s00259-025-07077-6","volume":"52","author":"X Long","year":"2025","unstructured":"Long X, Cheng S, Lan X, Wei W, Jiang D. Trends in nanobody radiotheranostics. Eur J Nucl Med Mol Imaging. 2025;52(6):2225\u201338.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"2","key":"4589_CR36","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1002\/cmmi.408","volume":"6","author":"LOT Gainkam","year":"2011","unstructured":"Gainkam LOT, Caveliers V, Devoogdt N, Vanhove C, Xavier C, Boerman O, et al. Localization, mechanism and reduction of renal retention of technetium-99m labeled epidermal growth factor receptor-specific nanobody in mice. Contrast Media Mol Imaging. 2011;6(2):85\u201392.","journal-title":"Contrast Media Mol Imaging"},{"issue":"8","key":"4589_CR37","doi-asserted-by":"publisher","first-page":"2444","DOI":"10.1007\/s00259-024-06672-3","volume":"51","author":"Q Wu","year":"2024","unstructured":"Wu Q, Wu Y, Zhang Y, Guan Y, Huang G, Xie F, et al. Immunopet\/CT imaging of clear cell renal cell carcinoma with [18F]RCCB6: a first-in-human study. Eur J Nucl Med Mol Imaging. 2024;51(8):2444\u201357.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"9","key":"4589_CR38","doi-asserted-by":"publisher","first-page":"2749","DOI":"10.1007\/s00259-021-05218-1","volume":"48","author":"C Wang","year":"2021","unstructured":"Wang C, Chen Y, Hou YN, Liu Q, Zhang D, Zhao H, et al. Immunopet imaging of multiple myeloma with [68Ga]Ga-NOTA-Nb1053. Eur J Nucl Med Mol Imaging. 2021;48(9):2749\u201360.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"4589_CR39","doi-asserted-by":"publisher","DOI":"10.34133\/research.0077","volume":"6","author":"Y Zhang","year":"2023","unstructured":"Zhang Y, Zhang D, An S, Liu Q, Liang C, Li J, et al. Development and characterization of nanobody-derived CD47 theranostic pairs in solid tumors. Research. 2023;6:0077.","journal-title":"Research"},{"issue":"21","key":"4589_CR40","doi-asserted-by":"publisher","first-page":"14623","DOI":"10.1021\/acs.jmedchem.3c01135","volume":"66","author":"Q Gan","year":"2023","unstructured":"Gan Q, Cui K, Cao Q, Zhang N, Yang MF, Yang X. Development of a 18F-labeled bicyclic peptide targeting EphA2 for molecular imaging of PSMA-negative prostate cancer. J Med Chem. 2023;66(21):14623\u201332.","journal-title":"J Med Chem"},{"issue":"7","key":"4589_CR41","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20071721","volume":"20","author":"C Morgat","year":"2019","unstructured":"Morgat C, Chastel A, Molinie V, Schollhammer R, Macgrogan G, V\u00e9lasco V, et al. Neurotensin receptor-1 expression in human prostate cancer: a pilot study on primary tumors and lymph node metastases. Int J Mol Sci. 2019;20(7):1721.","journal-title":"Int J Mol Sci"},{"key":"4589_CR42","doi-asserted-by":"crossref","unstructured":"Su Y, Liu Y, Behrens CR, Bidlingmaier S, Lee NK, Aggarwal R, et al. Targeting CD46 for both adenocarcinoma and neuroendocrine prostate cancer. JCI Insight. 2018;3(17):e121497, 121497.","DOI":"10.1172\/jci.insight.121497"},{"issue":"1","key":"4589_CR43","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-024-00599-6","volume":"8","author":"A Ajkunic","year":"2024","unstructured":"Ajkunic A, Sayar E, Roudier MP, Patel RA, Coleman IM, De Sarkar N, et al. Assessment of TROP2, CEACAM5 and DLL3 in metastatic prostate cancer: expression landscape and molecular correlates. NPJ Precis Oncol. 2024;8(1):104.","journal-title":"NPJ Precis Oncol"},{"key":"4589_CR44","doi-asserted-by":"crossref","unstructured":"Tendler S, Dunphy MP, Agee M, O\u2019Donoghue J, Aly RG, Choudhury NJ, et al. Imaging with [89Zr]Zr-DFO-SC16.56 anti-DLL3 antibody in patients with high-grade neuroendocrine tumours of the lung and prostate: a phase 1\/2, first-in-human trial. Lancet Oncol. 2024;25(8):1015\u201324.","DOI":"10.1016\/S1470-2045(24)00249-3"},{"issue":"9","key":"4589_CR45","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.2967\/jnumed.121.263132","volume":"63","author":"W Wu","year":"2022","unstructured":"Wu W, Yu F, Zhang P, Bu T, Fu J, Ai S, et al. 68Ga-DOTA-NT-20.3 neurotensin receptor 1 PET imaging as a surrogate for neuroendocrine differentiation of prostate cancer. J Nucl Med. 2022;63(9):1394\u2013400.","journal-title":"J Nucl Med"}],"container-title":["BMC Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12916-025-04589-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-025-04589-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-025-04589-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T12:53:30Z","timestamp":1770036810000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12916-025-04589-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,31]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4589"],"URL":"https:\/\/doi.org\/10.1186\/s12916-025-04589-8","relation":{},"ISSN":["1741-7015"],"issn-type":[{"value":"1741-7015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,31]]},"assertion":[{"value":"18 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The animal study protocol was approved by the Institutional Animal Care and Use Committee at Tongji Medical College, Huazhong University of Science and Technology (Approval Number: 4494). The human study was approved by the Ethics Committee of Renji Hospital, School of Medicine,\u00a0Shanghai Jiao Tong University (Approval Number: LY2024-307-A) and registered in ClinicalTrials.gov (NCT06851663). Written informed consent forms were obtained from all the included patients.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All patients gave written informed consent. All authors have read and approved of its submission to this journal.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"66"}}